Intestinal neuroendocrine tumor G1
MONDO:0021533A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the small or large intestine. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.
Also known as: carcinoid tumor of intestine, carcinoid tumor of the intestine, carcinoid tumour of intestine, carcinoid tumour of the intestine, grade 1 neuroendocrine neoplasm of intestine, intestinal NET G1, intestinal carcinoid tumor, intestinal carcinoid tumour
1477 clinical trials for this condition and its sub-types, 5 tagged with Intestinal neuroendocrine tumor G1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Intestinal neuroendocrine tumor G1
-
Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types
2 sub-types
- Ileal neuroendocrine tumor G1 3 trials
- Jejunal neuroendocrine tumor G1 0 trials
-
Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types
2 sub-types
- Colon neuroendocrine tumor G1 1 trial · 3 incl. sub-types Sub-types →
- Rectal neuroendocrine tumor G1 1 trial
Most studied deeper sub-types
-
Can more lutathera stop tumor progression? new study seeks answers
Disease control Recruiting nowThis study is for people with intestinal neuroendocrine tumors that have started growing again after initial treatment with Lutathera. It compares giving two more cycles of Lutathera versus simply monitoring the tumor over six months. The goal is to see if extra treatment can bet…
Phase 2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill aims to tame flushing and diarrhea in rare cancer syndrome
Symptom relief Recruiting nowThis Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Blood test may predict who benefits from targeted radiation therapy
Knowledge-focused Recruiting nowThis study looks at whether an inflammation-based score (using CRP and albumin levels) can predict how well patients with advanced intestinal neuroendocrine tumors respond to Lu-177 oxodotreotide therapy. Researchers will follow 150 patients for 36 months, collecting blood sample…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC